Connect with us

Private Companies

Awakn Life Sciences Drug Discovery Program Files Patent Application for a New Class of Entactogen-Like Molecules

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF), a biotechnology company developing and delivering psychedelic therapeutics to treat addiction, strengthened…

Published

on

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF), a biotechnology company developing and delivering psychedelic therapeutics to treat addiction, strengthened its intellectual property portfolio and pipeline for the treatment of addictions with the filing of a patent application for a new chemical series of entactogen-like molecules. Entactogen-like molecules are a class of psychoactive substances that produce distinctive emotional and social effects that Awakn believes has great potential to treat both substance and behavioural addictions.

Awakn’s latest patent application, which covers the new chemical series, fulfils another significant step forward in the development of next generation entactogens and provides a key milestone in Awakn’s drug discovery program. The application further strengthens Awakn’s pipeline and position as a global leader in the psychedelic-biotechnology industry.

“The novel entactogen-like molecules being developed at Awakn and protected in this patent, build on our recent filings to establish a strong pipeline of Novel Chemical Entities. These molecules have the potential to revolutionize the treatment of addiction by delivering improved efficacy in a shorter treatment time. Our aim is to treat addiction patients, more rapidly, effectively, and safely than has been possible to date.”

Professor David Nutt, Chief Research Officer at Awakn

Awakn and its research partner, Evotec, have used a combined Artificial Intelligence/Medicinal Chemistry approach to identify initial hits. A number of these hits were verified using a set of in vitro screening and ADMET assays leading to the identification of multiple patentable series.

Anthony Tennyson, Awakn’s CEO commented, “We are delighted with the pioneering progress we have made, and it is a testament to our world class team to have achieved another significant milestone in our drug discovery program. Increasing efficacy, while being able to deliver that in a shorter time frame, is what every biotech in this space is trying to do. We believe we have taken a big step in that direction with this patent application.”

About Awakn Life Sciences Corp.

Awakn Life Sciences is a biotechnology company, researching, developing, and delivering psychedelic therapeutics to better treat addiction. Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are advancing the next generation of psychedelic drugs and therapies to be used in combination.

Read More

Trending